Question 1

What is Gefitinib?

Accepted Answer

Gefitinib is a medication classified as a kinase inhibitor. It works by blocking the action of a specific protein that signals cancer cells to multiply.

By targeting these proteins, the medication helps to disrupt the signaling pathways that allow cancer cells to survive and spread. This process helps to slow or stop the progression of the disease.

Question 2

What is Gefitinib used for?

Accepted Answer

Gefitinib is used to treat EGFR mutation-positive non-small cell lung cancer .

Question 3

How does Gefitinib work?

Accepted Answer

Mechanism of Action

Gefitinib belongs to a class of medications known as tyrosine kinase inhibitors (TKIs). It is designed to target a specific protein called the epidermal growth factor receptor (EGFR), which is found on the surface of both normal and cancer cells.

In certain types of non-small cell lung cancer, the EGFR protein is mutated or overactive. This sends continuous signals to the cancer cells, telling them to grow, divide, and spread throughout the body. Gefitinib works by:

Binding to the EGFR protein inside the cancer cells.

Blocking the chemical signals that trigger cell division.

Interfering with the pathways that allow tumors to survive and grow.

Because gefitinib specifically targets these proteins, it is considered a targeted therapy. It is primarily used for cancers that have specific genetic markers, such as exon 19 deletions or exon 21 substitution mutations. These mutations are typically identified through laboratory testing of the tumor tissue before treatment begins.

Question 4

What are the brand names for Gefitinib?

Accepted Answer

Gefitinib is sold under the brand name Iressa .

Question 5

What are the active ingredients in Gefitinib?

Accepted Answer

The active ingredient in Gefitinib is gefitinib .

Question 6

What are the side effects of Gefitinib?

Accepted Answer

Common side effects of Gefitinib may include:

diarrhea

skin rash

acne

and others

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Gefitinib?

Accepted Answer

Gefitinib belongs to the EGFR tyrosine kinase inhibitor drug class.

Question 8

What is the dosage of Gefitinib and how do I take it?

Accepted Answer

How to Take Gefitinib

Gefitinib is taken by mouth, usually once a day. It is best to take the medication at the same time each day to maintain a consistent level in the bloodstream. You may take this medication with or without food.

The tablet should generally be swallowed whole with a glass of water. If you have difficulty swallowing tablets, you may disperse the tablet in a glass of non-carbonated drinking water. Stir the mixture until the tablet has broken up, then drink the liquid immediately. To ensure the full dose is taken, add more water to the same glass, stir, and drink it right away. Do not use other liquids to disperse the tablet.

Missed Dose

If you miss a dose, take it as soon as you remember. If it is nearly time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not take two doses at the same time to make up for a missed one.

Question 9

Is Gefitinib safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Gefitinib can cause harm to an unborn baby if taken during pregnancy. Animal studies have indicated that the medication may lead to decreased fetal weight and an increased risk of death in newborns. While there is limited data on the effects of gefitinib in pregnant humans, the way the drug works suggests it could interfere with normal fetal development.

Individuals who are able to become pregnant should discuss the risks with their healthcare provider. It is generally recommended to use effective contraception during treatment and for at least two weeks after the final dose of gefitinib. If a patient becomes pregnant while taking this medication, they should notify their doctor immediately.

Breastfeeding

It is not known whether gefitinib passes into human breast milk. Due to the potential for serious side effects in a breastfeeding infant, healthcare providers typically advise against breastfeeding while taking this medication. Patients should consult with their medical team to discuss the best way to feed their infant during treatment.

Question 10

What forms and strengths does Gefitinib come in?

Accepted Answer

Gefitinib is available as a film-coated tablet. It is an oral medication that is typically swallowed whole and can be taken with or without food.

Question 11

What is the FDA approval status of Gefitinib?

Accepted Answer

FDA Approval Status

Gefitinib is approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC). Its use is specifically indicated for patients whose tumors have certain epidermal growth factor receptor (EGFR) mutations, specifically exon 19 deletions or exon 21 (L858R) substitution mutations.

The FDA requires that these mutations be confirmed using an FDA-approved diagnostic test before a patient begins treatment with this medication.

Regulatory History

The regulatory status of gefitinib has changed significantly since its introduction:

It was first granted accelerated approval by the FDA in 2003.

In 2005, the FDA restricted its use to patients who were already participating in clinical trials or who had previously benefited from the drug, after larger studies failed to show a survival benefit in the general population.

In 2015, the FDA issued a new approval for gefitinib as a first-line treatment specifically for patients with the identified EGFR mutations.

Safety and Monitoring

There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements for gefitinib. The FDA-approved labeling includes pharmacogenomic information, which emphasizes the importance of biomarker testing to identify patients who are most likely to respond to the therapy.

Question 12

What should I know about Gefitinib and fda?

Accepted Answer

FDA-Approved Indications

The U.S. Food and Drug Administration (FDA) has approved gefitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC). This approval is specifically for patients whose tumors have certain epidermal growth factor receptor (EGFR) mutations, as detected by an FDA-approved test.

The specific genetic markers targeted by this medication include:

Exon 19 deletions

Exon 21 (L858R) substitution mutations

Testing Requirements

The FDA requires that the presence of these specific EGFR mutations be confirmed using a validated diagnostic test before starting treatment. Gefitinib is not indicated for use in patients whose tumors do not harbor these specific mutations, as its safety and efficacy have not been established for the general lung cancer population.

Regulatory History

Gefitinib was originally granted accelerated approval by the FDA in 2003. However, after subsequent clinical trials failed to demonstrate a survival benefit in the general patient population, its use was restricted for several years. In 2015, the FDA issued a new approval for gefitinib as a targeted first-line therapy for the specific subset of patients with EGFR-positive metastatic NSCLC.

Gefitinib

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Fda Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?